Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy

Vincenza Conteduca, Sheng-Yu Ku, Loredana Puca, Megan Slade, Luisa Fernandez, Judy Hess, Rohan Bareja, Panagiotis J. Vlachostergios, Michael Sigouros, Juan Miguel Mosquera, Andrea Sboner, David M. Nanus, Olivier Elemento, Ryan Dittamore, Scott T. Tagawa and Himisha Beltran
Vincenza Conteduca
1Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
2Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vincenza Conteduca
Sheng-Yu Ku
1Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loredana Puca
3Weill Cornell Medicine, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megan Slade
4Epic Sciences, Inc., San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Megan Slade
Luisa Fernandez
4Epic Sciences, Inc., San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judy Hess
3Weill Cornell Medicine, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rohan Bareja
3Weill Cornell Medicine, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Panagiotis J. Vlachostergios
3Weill Cornell Medicine, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Panagiotis J. Vlachostergios
Michael Sigouros
3Weill Cornell Medicine, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Sigouros
Juan Miguel Mosquera
3Weill Cornell Medicine, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Sboner
3Weill Cornell Medicine, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrea Sboner
David M. Nanus
3Weill Cornell Medicine, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Elemento
3Weill Cornell Medicine, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan Dittamore
4Epic Sciences, Inc., San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ryan Dittamore
Scott T. Tagawa
3Weill Cornell Medicine, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Scott T. Tagawa
Himisha Beltran
1Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
3Weill Cornell Medicine, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: himisha_beltran@dfci.harvard.edu
DOI: 10.1158/1535-7163.MCT-19-0926 Published May 2020
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: March 2020 to January 2021

AbstractFull-text HTMLPDF
Total3561218625

Cited By

Article Information

Volume 19, Issue 5, pp. 1157-1164

DOI 
https://doi.org/10.1158/1535-7163.MCT-19-0926
PubMed 
32127465

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received October 4, 2019
  • Revision received December 7, 2019
  • Accepted February 13, 2020
  • Published first March 3, 2020.

Article Versions

  • Previous version (March 3, 2020 - 06:59).
  • Previous version (April 21, 2020 - 07:50).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2020 American Association for Cancer Research.

Author Information

  1. Vincenza Conteduca1,2,
  2. Sheng-Yu Ku1,
  3. Loredana Puca3,
  4. Megan Slade4,
  5. Luisa Fernandez4,
  6. Judy Hess3,
  7. Rohan Bareja3,
  8. Panagiotis J. Vlachostergios3,
  9. Michael Sigouros3,
  10. Juan Miguel Mosquera3,
  11. Andrea Sboner3,
  12. David M. Nanus3,
  13. Olivier Elemento3,
  14. Ryan Dittamore4,
  15. Scott T. Tagawa3, and
  16. Himisha Beltran1,3,*
  1. 1Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  2. 2Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  3. 3Weill Cornell Medicine, New York, New York.
  4. 4Epic Sciences, Inc., San Diego, California.
  1. ↵*Corresponding Author:
    Himisha Beltran, Dana Farber Cancer Institute, 450 Brookline Avenue, Sm 758, Boston, MA 02215. Phone: 617-582-9421; Fax: 617-632-2165; E-mail: himisha_beltran{at}dfci.harvard.edu
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 19 (5)
May 2020
Volume 19, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy
Vincenza Conteduca, Sheng-Yu Ku, Loredana Puca, Megan Slade, Luisa Fernandez, Judy Hess, Rohan Bareja, Panagiotis J. Vlachostergios, Michael Sigouros, Juan Miguel Mosquera, Andrea Sboner, David M. Nanus, Olivier Elemento, Ryan Dittamore, Scott T. Tagawa and Himisha Beltran
Mol Cancer Ther May 1 2020 (19) (5) 1157-1164; DOI: 10.1158/1535-7163.MCT-19-0926

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy
Vincenza Conteduca, Sheng-Yu Ku, Loredana Puca, Megan Slade, Luisa Fernandez, Judy Hess, Rohan Bareja, Panagiotis J. Vlachostergios, Michael Sigouros, Juan Miguel Mosquera, Andrea Sboner, David M. Nanus, Olivier Elemento, Ryan Dittamore, Scott T. Tagawa and Himisha Beltran
Mol Cancer Ther May 1 2020 (19) (5) 1157-1164; DOI: 10.1158/1535-7163.MCT-19-0926
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Material and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • HLA Polymorphisms Predict TFR in CML
  • Olaratumab-Induced Biomarker Modulation in Sarcomas
  • TP53 Mutations: Tissue versus Liquid Biopsy Survival Implication
Show more Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement